eViralHepatitis Review - Volume 6, Issue 1 - HCV Complications in Special Populations

Volume 6, Issue 1

HCV Complications in Special Populations

In this issue:

Not too long ago, “special populations” of hepatitis C infection referred to patients failing to achieve SVR with the currently available DAA therapies. Now, as therapeutic efficacy has progressed, the concept of special populations has shifted focus to include treatment of people affected by HCV-related hepatic and extrahepatic manifestations.

In this issue, Dr. Paul Martin and Dr. Kalyan Ram Bhamidimarri of the University of Miami analyze recent publications on managing HCV complications in special populations — patients with chronic kidney disease, cryoglobulinemia, cirrhosis, and HIV coinfection, and those receiving transplant organs from HCV-infected donors.

Learning objectives:

Describe HCV-associated cryoglobulinemic vasculitis and the strategies to manage HCV infection in CKD patients.
Review the data on association of DAA therapy and the development of HCC and on donor-derived HCV transmission.
Discuss the role of DAA therapy on liver fibrosis in patients with HCV-HIV coinfection.

Authors:

Paul Martin, MD, FRCP, FRCPI
Professor of Medicine, Chief Division of Gastroenterology/Hepatology
University of Miami School of Medicine
Miami, Florida

Kalyan Ram Bhamidimarri, MD, MPH
Associate Professor of Clinical Medicine
Medical Director for Small Bowel & Multi-Visceral Transplantation
University of Miami School of Medicine
Miami Transplant Institute
Miami, Florida

Guest Faculty Disclosures

Dr. Martin has disclosed that he has served as a principal investigator and consultant for Gilead Sciences, Inc., AbbVie, Inc., and Merck & Co, Inc.

Dr. Bhamidimarri has disclosed that he has served as a principal investigator on a scientific advisory board for Gilead Sciences, Inc. He has also served as a principal investigator for Mallinckrodt, Inc. and Vital Therapies. He has served on scientific advisory boards for Abbott Laboratories, Intercept, and Merck & Co., Inc. And he has received consulting fees from Alexion.

Unlabeled/Unapproved Uses

Dr. Martin and Dr. Bhamidimarri have indicated that there will be no references to the unlabeled or unapproved uses of any drugs or products.

Program Directors:

Mark S. Sulkowski, MD

Professor of Medicine
Division of Infectious Diseases
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology and Hepatology
Johns Hopkins School of Medicine
Baltimore, Maryland

Raymond T. Chung, MD

Director of Hepatology and Liver Center
Vice Chief, Gastroenterology
Kevin and Polly Maroni Research Scholar
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Taryn Haselhuhn, BA, BSN, MSN, CRNP
The Johns Hopkins Hospital
Baltimore, Maryland

Guest Faculty Disclosures:

Dr. Martin has disclosed that he has served as a principal investigator and consultant for Gilead Sciences, Inc., AbbVie, Inc., and Merck & Co, Inc.

Unlabeled/Unapproved Uses:

Dr. Martin and Dr. Bhamidimarri have indicated that there will be no references to the unlabeled or unapproved uses of any drugs or products.

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: September 28, 2018
Expiration date: September 27, 2020

Start Issue